Related Experiment Video
Updated: Jun 3, 2026
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges
M Kelly Nicholas1, Rimas V Lukas, Steven Chmura
1Department of Neurology, University of Chicago, Chicago, IL 60637, USA. mnichola@neurology.bsd.uchicago.edu
Abstract:
Glioblastoma (GBM) has been recognized as a clinical and pathologic entity for more than a century. Throughout its history, its cells of origin have been in question. Its behavior is aggressive and despite decades of effort, median survival is just beginning to improve. Surgical techniques and radiotherapy schemas continue to be refined, but the most recent progress has been achieved through improved medical therapies. These are the result of both pharmacological advances and a deeper understanding of the biological characteristics of GBM. Due to a combination of its complex phenotype and organ-specific clinical manifestations, efforts to refine GBM treatment with targeted therapies largely have been frustrated. In this review, we discuss recent attempts to exploit new molecular insights, consider the reasons for slow progress in developing better treatments, and examine future therapeutic options.
Insights
Glioblastoma (GBM) remains aggressive despite advances. This review explores recent molecular insights, challenges in targeted therapy, and future glioblastoma treatment options.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Translational Medicine
Background:
- Glioblastoma (GBM) is a long-recognized, aggressive brain tumor with historically poor prognosis.
- Despite over a century of study, the precise cells of origin for GBM remain debated.
- Median patient survival for GBM is only recently showing improvement, highlighting the need for better therapies.
Purpose of the Study:
- To review recent therapeutic strategies for glioblastoma.
- To analyze the challenges hindering targeted therapy development for GBM.
- To discuss future directions for glioblastoma treatment based on molecular insights.
Main Methods:
- Literature review of recent advances in glioblastoma research.
- Analysis of molecular characteristics influencing GBM biology and treatment response.
- Examination of clinical trial outcomes and therapeutic strategies.
Main Results:
- Progress in GBM treatment is primarily driven by improved medical therapies, including pharmacological advances.
- Targeted therapy development for GBM has been significantly challenged by its complex phenotype and clinical variability.
- Recent molecular insights offer potential avenues for novel treatment approaches.
Conclusions:
- Future glioblastoma treatment will likely integrate refined surgical and radiotherapy techniques with advanced pharmacological and targeted therapies.
- Overcoming the complexities of GBM biology is crucial for developing more effective treatments.
- Continued research into molecular mechanisms and therapeutic resistance is essential for improving patient outcomes in glioblastoma.
